keyword
MENU ▼
Read by QxMD icon Read
search

Proton pump inhibitors and cancer

keyword
https://www.readbyqxmd.com/read/29770171/risk-of-gastric-cancer-development-after-eradication-of-helicobacter-pylori
#1
REVIEW
Ka-Shing Cheung, Wai K Leung
Helicobacter pylori ( H. pylori ) infection is the most important risk factor for gastric cancer (GC) development through the Correa's gastric carcinogenesis cascade. However, H. pylori eradication alone does not eliminate GC, as pre-neoplastic lesions (atrophic gastritis, intestinal metaplasia and dysplasia) may have already developed in some patients. It is therefore necessary to identify patients at high-risk for gastric cancer after H. pylori eradication to streamline the management plan. If the patients have not undergone endoscopy with histologic assessment, the identification of certain clinical risk factors and non-invasive testing (serum pepsinogen) can predict the risk of atrophic gastritis...
May 15, 2018: World Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29741272/proton-pump-inhibitor-and-histamine-2-receptor-antagonist-use-and-risk-of-liver-cancer-in-two-population-based-studies
#2
K T Tran, Ú C McMenamin, B Hicks, P Murchie, A P Thrift, H G Coleman, L Iversen, B T Johnston, A J Lee, C R Cardwell
BACKGROUND: Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are commonly used. PPIs have been shown to promote liver cancer in rats; however, only one study has examined the association in humans. AIMS: To investigate PPIs and H2RAs and risk of primary liver cancer in two large independent study populations. METHODS: We conducted a nested case-control study within the Primary Care Clinical Informatics Unit (PCCIU) database in which up to five controls were matched to cases with primary liver cancer, recorded by General Practitioners...
May 9, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29661803/proton-pump-inhibitors-and-risk-of-gastric-cancer-in-a-case-control-study
#3
Shih-Wei Lai, Hsueh-Chou Lai, Cheng-Li Lin, Kuan-Fu Liao
No abstract text is available yet for this article.
April 16, 2018: Gut
https://www.readbyqxmd.com/read/29658114/proton-pump-inhibitor-use-and-cancer-mortality
#4
Siri A Tvingsholm, Christian Dehlendorff, Kell Østerlind, Søren Friis, Marja Jäättelä
Proton pump inhibitors (PPIs) are commonly used as a supplement to cancer therapy. Yet, their effect on cancer mortality is largely unknown. Using data from Danish nationwide registries and Cox models regressing of both propensity scores and drug use, we estimated hazard ratios (HRs) with 95% confidence intervals (CIs) for cancer-specific and noncancer death among PPI users (≥2 prescriptions within six months after diagnosis; n = 36,066) compared with nonusers (<2 prescriptions, n = 311,853) or users of histamine H2 -receptor antagonists (H2 RA; n = 5,152)...
April 15, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29615489/long-term-proton-pump-inhibitors-use-and-risk-of-gastric-cancer-a-meta-analysis-of-926-386-participants
#5
Qian-Yi Wan, Xiao-Ting Wu, Ni Li, Liang Du, Yong Zhou
No abstract text is available yet for this article.
April 3, 2018: Gut
https://www.readbyqxmd.com/read/29599181/proton-pump-inhibitor-therapy-after-helicobacter-pylori-eradication-may-increase-the-risk-of-gastric-cancer
#6
REVIEW
Mimi Chang Tan, David Y Graham
No abstract text is available yet for this article.
March 29, 2018: BMJ evidence-based medicine
https://www.readbyqxmd.com/read/29520199/helicobacter-pylori-treatment-results-in-slovenia-in-the-period-2013-2015-as-a-part-of-european-registry-on-helicobacter-pylori-management
#7
Bojan Tepes, Marko Kastelic, Miroslav Vujasinovic, Polona Lampic, Maja Seruga, Natasa Brglez Jurecic, Olga P Nyssen, Maria G Donday, Colm O'Morain, Francis Megraud, Adrian G McNicholl, Javier P Gisbert
Background: Helicobacter pylori (H. pylori) is the most common chronic bacterial infection in the world affecting over 50% of the world's population. H. pylori is a grade I carcinogen, responsible for the development of 89 % of noncardia gastric cancers. In the present study we analyzed the data for H. pylori eradication treatments in Slovenia. Patients and methods: Slovenia is a part of the European Registry on Helicobacter pylori Management from the beginning...
March 2018: Radiology and Oncology
https://www.readbyqxmd.com/read/29509282/medicare-part-d-use-of-older-medicare-beneficiaries-admitted-to-hospice
#8
Patrick M Zueger, Holly M Holmes, Gregory S Calip, Dima M Qato, A Simon Pickard, Todd A Lee
OBJECTIVES: To describe medications that older hospice beneficiaries receive through Medicare Part D and assess patterns in Part D use for individuals admitted to hospice for cancer and noncancer causes. DESIGN: Descriptive cohort analysis using the Surveillance, Epidemiology and End Results (SEER)-Medicare linked database. SETTING: U.S. hospice programs PARTICIPANTS: Part D-enrolled Medicare beneficiaries aged 66 and older who were admitted to hospice and died while under hospice care between January 1, 2008, and December 31, 2013 (N = 88,957)...
March 6, 2018: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/29504332/gastro-oesophageal-reflux-diseases-in-chronic-obstructive-pulmonary-disease-patients
#9
Hamid Nisar Khan, Amir Suleman, Raza Ullah, Azmat Abdullah, Shahida Naz
BACKGROUND: There is an association of Gastroesophageal reflux disease (GERD) with chronic obstructive pulmonary disease (COPD). This study was designed to determine the frequency of GERD in COPD patients. METHODS: This descriptive, cross-sectional study was conducted in the Pulmonology Unit Ayub Teaching Hospital Abbottabad. Patients more than 40 years of age of both genders presenting with features of COPD such as cough and breathlessness for more than 6 months and confirmed by spirometry were included in the study...
January 2018: Journal of Ayub Medical College, Abbottabad: JAMC
https://www.readbyqxmd.com/read/29488678/monotherapy-with-a-novel-intervenolin-derivative-as-1934-is-an-effective-treatment-for-helicobacter-pylori-infection
#10
Tomokazu Ohishi, Tohru Masuda, Hikaru Abe, Chigusa Hayashi, Hayamitsu Adachi, Shun-Ichi Ohba, Masayuki Igarashi, Takumi Watanabe, Hitomi Mimuro, Eri Amalia, Daniel Ken Inaoka, Kota Mochizuki, Kiyoshi Kita, Masakatsu Shibasaki, Manabu Kawada
BACKGROUND: Helicobacter pylori (H. pylori) infection causes various gastrointestinal diseases including gastric cancer. Hence, eradication of this infection could prevent these diseases. The most popular first-line treatment protocol to eradicate H. pylori is termed "triple therapy" and consists of a proton pump inhibitor (PPI), clarithromycin, and amoxicillin or metronidazole. However, the antibiotics used to treat H. pylori infection are hindered by the antibiotics-resistant bacteria and by their antimicrobial activity against intestinal bacteria, leading to side effects...
April 2018: Helicobacter
https://www.readbyqxmd.com/read/29486725/immune-checkpoint-inhibitor-nivolumab-associated-kidney-injury-and-the-importance-of-recognizing-concomitant-medications-known-to-cause-acute-tubulointerstitial-nephritis-a-case-report
#11
Ryo Koda, Hirofumi Watanabe, Masafumi Tsuchida, Noriaki Iino, Kazuo Suzuki, Go Hasegawa, Naofumi Imai, Ichiei Narita
BACKGROUND: Acute tubulointerstitial nephritis (ATIN) has been increasingly recognized as an important manifestation of kidney injury associated with the use of immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4). While the exact pathophysiology remains unknown, corticosteroids are the mainstay of management. CASE PRESENTATION: We describe a 67-year-old man with stage IV non-small-cell lung cancer who developed kidney injury during treatment with the anti-PD-1 antibody nivolumab...
February 27, 2018: BMC Nephrology
https://www.readbyqxmd.com/read/29477057/maintenance-proton-pump-inhibition-therapy-and-risk-of-oesophageal-cancer
#12
Nele Brusselaers, Lars Engstrand, Jesper Lagergren
BACKGROUND: The association of long-term use of proton pump inhibitors (PPIs) with oesophageal adenocarcinoma has been poorly defined. Our aim was to assess the risk of oesophageal cancer assessing confounding by indication. METHODS: This population-based cohort study included all 796,492 adults exposed to maintenance therapy with PPIs in Sweden in 2005-2012. Standardised incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated to assess the risk of oesophageal adenocarcinoma (and squamous cell carcinoma as a comparison) among long-term PPI users relative to the corresponding background population...
April 2018: Cancer Epidemiology
https://www.readbyqxmd.com/read/29472295/association-between-proton-pump-inhibitors-use-and-risk-of-gastric-cancer-in-patients-with-gerd
#13
Yen-Chun Peng, Lam-Ru Huang, Cheng-Li Lin, Wan-Yun Hsu, Chi-Sen Chang, Hong-Zen Yeh, Chia-Hung Kao
No abstract text is available yet for this article.
February 22, 2018: Gut
https://www.readbyqxmd.com/read/29436014/comparison-of-dysplastic-fundic-gland-polyps-in-patients-with-and-without-familial-adenomatous-polyposis
#14
Shana F Straub, Michael G Drage, Raul S Gonzalez
AIMS: Dysplastic fundic gland polyps (d-FGPs) typically arise in patients with familial adenomatous polyposis (FAP) but may occur in non-syndromic patients. They rarely become malignant, but their significance is unclear, especially in non-syndromic patients. We aimed to compare d-FGPs in patients with and without FAP, using clinicopathologic findings and β-catenin immunohistochemistry (IHC). METHODS AND RESULTS: We identified 124 fundic gland polyps with low-grade dysplasia (LGD) or high-grade dysplasia (HGD) or indefinite for dysplasia (IFD) from 66 patients (27 with FAP; 39 non-syndromic)...
February 12, 2018: Histopathology
https://www.readbyqxmd.com/read/29431404/hoarseness-in-adults
#15
Steven A House, Eric L Fisher
Hoarseness is a common presentation in primary care practices. Combined with other voice-related changes, it falls under the umbrella diagnosis of dysphonia. Hoarseness has a number of causes, ranging from simple inflammatory processes to less common psychiatric disorders to more serious systemic, neurologic, or cancerous conditions. Medication-induced hoarseness is common and should be considered. The initial evaluation begins with a targeted history and physical examination, while also looking for signs of potential systemic etiologies...
December 1, 2017: American Family Physician
https://www.readbyqxmd.com/read/29391326/use-of-proton-pump-inhibitors-and-risk-of-gastric-cancer
#16
COMMENT
Tarkan Karakan
No abstract text is available yet for this article.
January 2018: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/29376210/first-in-human-phase-i-dose-escalation-study-of-mk-8033-in-patients-with-advanced-solid-tumors
#17
Vicki L Keedy, Heinz-Josef Lenz, Leonard Saltz, Jennifer G Whisenant, Jordan D Berlin, Luis H Camacho
Background C-Met, which is frequently activated in multiple cancers, has been implicated in tumor formation, progression, metastasis, angiogenesis, and resistance to multiple therapies. MK-8033 is a small-molecule inhibitor of c-Met that binds preferentially to the activated conformation, and has demonstrated anti-tumor activity in preclinical models. This first-in-human trial was performed to establish the safety and maximum tolerated dose (MTD), as well as preliminary pharmacokinetics (PK) and clinical activity...
January 29, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29337457/-pharmacovigilance-update
#18
Françoise Livio
The main pharmacovigilance updates in 2017 are reviewed. Denosumab : rebound-associated multiple vertebral fractures after discontinuation. Canagliflozine: increased risk of foot/leg amputations. Biologic and targeted cancer therapies, direct-acting antivirals for chronic hepatitis C: risk of hepatitis B reactivation. Checkpoint inhibitors : immune-related adverse events and graft rejection. Fingolimod : rebound-associated reactivation of MS following withdrawal. Daclizumab: risk of severe liver injury leading to restricted use in MS patients...
January 10, 2018: Revue Médicale Suisse
https://www.readbyqxmd.com/read/29298870/proton-pump-inhibitors-and-increased-gastric-cancer-risk-time-related-biases
#19
Samy Suissa, Alain Suissa
No abstract text is available yet for this article.
January 3, 2018: Gut
https://www.readbyqxmd.com/read/29273641/long-term-proton-pump-inhibitor-use-is-a-risk-factor-of-gastric-cancer-after-treatment-for-helicobacter-pylori-a-retrospective-cohort-analysis
#20
Ryota Niikura, Yoku Hayakawa, Yoshihiro Hirata, Atsuo Yamada, Mitsuhiro Fujishiro, Kazuhiko Koike
No abstract text is available yet for this article.
December 22, 2017: Gut
keyword
keyword
114620
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"